Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 7
Encontrada(s) 1 página(s)

RODIN. Repositorio de Objetos de Docencia e Investigación de la Universidad de Cádiz
Publication Artículo científico (JournalArticle)

Exploring a Novel Anti-Inflammatory Therapy for Diabetic Retinopathy Based on Glyco-Zeolitic-Imidazolate Frameworks

  • Díaz-Paredes, E.
  • Martín Loro, Francisco
  • Rodríguez-Marín, R.
  • Gómez Jaramillo, María Laura
  • Sánchez-Fernández, Elena M.
  • Carrillo-Carrión, Carolina
  • Arroba Espinosa, Ana Isabel
Background/Objectives: Diabetic retinopathy is an ocular disease caused by changes in the expression of inflammatory mediators and increased oxidative stress in the retina and is the leading cause of vision loss in diabetic patients. Currently, there is no treatment capable of reversing retinal damage, which represents a significant burden on the quality of life of patients. (1R)-1-Dodecylsulfonyl-5N,6O-oxomethylidenenojirimycin stands outs as a prototype of the sp2 -iminoglycolipids family for its beneficial neuroprotective effect against this chronic eye disease. Critical issues related to the low solubility and bioavailability of this glycolipid in biological settings are overcome by its encapsulation in a Zeolitic-Imidazolate Framework (ZIF) structure, resulting in homogeneous and biocompatible GlycoZIF nanoparticles. Cell studies show an enhanced cellular uptake compared with the free glycolipid, and importantly, its bioactivity is preserved once released inside cells. Methods: Extensive in vitro and ex vivo assays with diabetic retinopathy models unveil the mechanistic pathways of the designed GlycoZIF. Results: A reduction in proinflammatory mediators, increased heme oxygenase-1 level, inhibition of NLRP3 inflammasome, and reduced reactive gliosis is shown. Conclusions: These findings demonstrate for the first time the potential of Glyco-modified ZIFs for the treatment of diabetes-related ocular problems by controlling the immune-mediated inflammatory response.
RODIN. Repositorio de Objetos de Docencia e Investigación de la Universidad de Cádiz
Publication Tesis doctoral (DoctoralThesis)

Identificación de los perfiles inmunológicos e inflamatorios relacionados con la progresión de la diabetes mellitus tipo 1 y sus complicaciones asociadas

  • Martín Loro, Francisco
La diabetes mellitus tipo 1 (DM1) es una enfermedad autoinmunitaria crónica caracterizada por la destrucción selectiva de las células-pancreáticas productoras de insulina, localizadas en los islotes de Langerhans. Esta pérdida conduce a una deficiencia absoluta de insulina y, en consecuencia, a una hiperglucemia sostenida. La DM1 representa entre el 5-10% de todos los casos de diabetes y suele manifestarse en la infancia o adolescencia, aunque puede aparecer a cualquier edad. Su etiología es multifactorial, involucrando una compleja interacción entre predisposición genética, factores ambientales y disfunción inmunitaria. Desde el punto de vista inmunológico, la patogenia de la DM1 se inicia con la presentación de antígenos derivados de las células a través de las células dendríticas y los macrófagos. La respuesta autoinmune mediada por el reconocimiento de estos antígenos por los linfocitos T, requiere de la participación de distintas citoquinas que inducen el perfil Th1 o reactivo de los linfocitos T. Esta producción de citoquinas contribuye a generar el ambiente necesario para activar la respuesta citotóxica de los macrófagos sobre las células. Paralelamente, se generan autoanticuerpos frente a antígenos específicos como GAD65, IA-2 e insulina, que sirven como marcadores serológicos de autoinmunidad. En contraste, la participación de linfocitos Th2, favorece un papel más regulador y antiinflamatorio. No obstante, en la DM1 predomina un desequilibrio de las poblaciones linfocitarias e inmunes, lo que perpetúa la inflamación crónica y el daño tisular. A nivel inflamatorio, el islote pancreático de pacientes con DM1 muestra infiltración linfocitaria (insulitis), producción elevada de citoquinas proinflamatorias (TNF-, IL-1, IFN-) y activación de vías de estrés oxidativo. Estos procesos amplifican la muerte celular y la exposición de nuevos autoantígenos, alimentando un ciclo autoinmunitario permanente. En conjunto, la DM1 representa un modelo paradigmático de autoinmunidad mediada por células, donde la interacción entre genética, inmunidad e inflamación culmina en la pérdida irreversible de la función pancreática endocrina. Los cambios sistémicos inmunes detectados a lo largo del progreso de la DM1, no solo afectan al páncreas endocrino, como órgano diana de la enfermedad; si no que las complicaciones asociadas a la DM1 pueden verse influenciadas por estas respuestas tempranas, condicionando su aparición, así como su progresión. Debido al interés de los procesos descritos en el desarrollo y progresión de la DM1, así como su relación con el desarrollo de la retinopatía diabética, esta tesis ha sido estructurada en tres estudios interconectados, que abordan aspectos inflamatorios, inmunológicos y potencialmente terapéuticos en cada uno de ellos, como se expone en los siguientes apartados: En el primer estudio se analizaron los cambios inmunológicos en PBMCs de pacientes con DM1 mediante citometría de flujo y análisis génico. Se detectaron alteraciones en la composición celular, con aumento de linfocitos T CD4, disminución de T CD8 y NK, y un patrón bifásico en las células Th17. A nivel molecular, se observó una polarización inmunitaria caracterizada por alta expresión de RORCT y FOXP3, junto con la persistencia de TNFB e IFNG y variaciones en IL-1B e IL-8. Además, genes antiinflamatorios como ARG1 y HMOX1 se sobre expresaron en etapas iniciales, sugiriendo mecanismos compensatorios. El tratamiento con un compuesto sintético, que se fundamenta en estructuras de origen marino (M9), redujo los niveles de expresión de mediadores proinflamatorios e indujo una respuesta antiinflamatoria. En conjunto, los resultados indican que la DM1 progresa mediante un equilibrio dinámico entre respuestas inflamatorias y reguladoras, y que nuevas moléculas bioactivas podrían tener un valor terapéutico inmunomodulador. En el segundo estudio se evaluaron 74 pacientes con DM1 divididos según la duración de la enfermedad (A: <3 meses; B: 3 meses-1 año; C: 1-5 años; D: >5 años) y 23 controles sanos. Se analizaron niveles séricos de citoquinas pro y antiinflamatorias, parámetros bioquímicos y características retinianas mediante tomografía de coherencia óptica (OCT). Los resultados mostraron un aumento de citoquinas proinflamatorias (IL-1, TNF-, IL18, IL-12Ra, IL-8, MCP-1, MIF, IP10, M-CSF) en etapas iniciales (grupo A) y una combinación de citoquinas proinflamatorias (Eotaxina, IL-8, IL-2Ra, MCP-1, MIG, IL12(p70), IL-17) y antiinflamatorias (IL-4, LIF) en fases intermedias (grupo C). Además, se observó una correlación entre los niveles de citoquinas proinflamatorias y signos tempranos de RD, como el adelgazamiento retiniano y el aumento del área avascular foveal y la neovascularización en los grupos C y D. En conjunto, los perfiles de citoquinas identificados reflejan una evolución inmunológica dinámica durante la DM1 y podrían servir como biomarcadores inmunes útiles para mejorar el diagnóstico, pronóstico y manejo clínico de la enfermedad y sus complicaciones oculares. En el tercer estudio se analizaron los mecanismos asociados a su progresión, para ello se estudiaron pacientes divididos en dos grupos según la duración de la enfermedad: Early (12 meses) y Advanced (>12 meses), junto con un grupo control sano (H). Mediante análisis proteómico de PBMCs y cuantificación sérica de mediadores inflamatorios, se identificaron proteínas diferencialmente expresadas implicadas en el transporte vesicular, la respuesta inmune y el metabolismo. Varias proteínas asociadas a la vía de señalización de IL-12 en macrófagos (APOA2, APOC1, APOC3, PON1, AAK1 y CBL) mostraron una regulación negativa. Los niveles séricos de IL-12 fueron significativamente mayores en el grupo Early respecto al control (p<0.001), mientras que en el grupo Advanced solo se observó una tendencia al alza. La proteína CBL se propuso como un marcador del estado inmunológico durante la progresión de la DM1, y HRG como un biomarcador potencial de complicaciones secundarias, como la retinopatía diabética. En conjunto, estos resultados aportan información clave sobre los mecanismos inmuno-metabólicos de la enfermedad y podrían guiar nuevas estrategias diagnósticas y terapéuticas. En conjunto, los resultados de este trabajo evidencian que la progresión de la DM1 está marcada por una interacción dinámica entre mecanismos inflamatorios y reguladores del sistema inmunitario. Los perfiles específicos de citoquinas y proteínas identificados no solo reflejan el estado inmunológico en las distintas etapas de la enfermedad, sino que además se perfilan como biomarcadores potenciales para mejorar el diagnóstico, el pronóstico y la prevención de complicaciones secundarias como la retinopatía diabética. Asimismo, la respuesta positiva observada frente a compuestos bioactivos con propiedades inmunomoduladoras sugiere un potencial terapéutico prometedor orientado a modular la inflamación, optimizar el manejo clínico y favorecer mejores resultados a largo plazo en pacientes con DM1., Type 1 diabetes mellitus (DM1) is a chronic autoimmune disease characterized by the selective destruction of insulin-producing pancreatic β-cells located within the islets of Langerhans. This loss results in absolute insulin deficiency and, consequently, sustained hyperglycemia. DM1 accounts for approximately 5-10% of all diabetes cases and typically manifests during childhood or adolescence, although it may occur at any age. Its etiology is multifactorial, involving a complex interplay among genetic predisposition, environmental factors, and immune dysfunction. From an immunological perspective, the pathogenesis of DM1 begins with the presentation of β-cell–derived antigens by dendritic cells and macrophages. The ensuing autoimmune response, mediated by T-lymphocyte recognition of these antigens, requires the participation of cytokines that promote a Th1-type or proinflammatory T-cell profile. This cytokine production contributes to creating an environment that enables macrophage-mediated cytotoxic activity against β-cells. In parallel, autoantibodies targeting antigens such as GAD65, IA-2, and insulin are generated and serve as serological markers of autoimmunity. In contrast, the involvement of Th2 lymphocytes favors a more regulatory and antiinflammatory role. However, in DM1, an imbalance among lymphocyte and immune cell populations predominates, perpetuating chronic inflammation and tissue damage. At the inflammatory level, the pancreas of individuals with DM1 exhibits lymphocytic infiltration (insulitis), increased production of proinflammatory cytokines (TNF-α, IL-1β, IFN-γ), and activation of oxidative stress pathways. These processes amplify cell death and the exposure of new autoantigens, fueling a persistent autoimmune cycle. Altogether, DM1 represents a paradigmatic model of cell-mediated autoimmunity, in which interactions among genetics, immunity, and inflammation culminate in irreversible loss of endocrine pancreatic function. Systemic immune changes detected throughout the progression of DM1 not only affect the pancreas as the primary target organ but may also influence DM1-associated complications, conditioning their onset and progression. Owing to the relevance of these processes in the development and progression of DM1 and their relationship with diabetic retinopathy, this thesis is structured into three interconnected studies that explore inflammatory, immunological, and potentially therapeutic aspects, as outlined below: In the first study, immunological changes in PBMCs from DM1 patients were analyzed by flow cytometry and gene expression profiling. Alterations in cellular composition were detected, including an increase in CD4⁺ T lymphocytes, a decrease in CD8⁺ T cells and NK cells, and a biphasic pattern in Th17 cells. At the molecular level, an immune polarization characterized by high expression of RORγt and FoxP3, along with persistent TNFB and IFNG expression and variations in IL-1B and IL-8, was observed. Additionally, anti-inflammatory genes such as ARG1 and HMOX1 were overexpressed in early stages, suggesting compensatory mechanisms. Treatment with a synthetic compound based on marine-derived structures (M9) reduced the expression of proinflammatory mediators and induced an anti-inflammatory response. Overall, the findings indicate that DM1 progresses through a dynamic balance between inflammatory and regulatory responses, and that novel bioactive molecules may hold immunomodulatory therapeutic potential. In the second study, 74 DM1 patients were evaluated and classified according to disease duration (A: <3 months; B: 3 months–1 year; C: 1–5 years; D: >5 years), along with 23 healthy controls. Serum levels of pro- and anti-inflammatory cytokines, biochemical parameters, and retinal characteristics assessed by optical coherence tomography (OCT) were analyzed. The results showed an increase in proinflammatory cytokines (IL-1β, TNF-α, IL-18, IL12Ra, IL-8, MCP-1, MIF, IP-10, M-CSF) in early stages (group A) and a combination of proinflammatory (Eotaxin, IL-8, IL-2Ra, MCP-1, MIG, IL-12(p70), IL-17) and antiinflammatory cytokines (IL-4, LIF) in intermediate stages (group C). Moreover, correlations were observed between proinflammatory cytokine levels and early signs of diabetic retinopathy, such as retinal thinning, increased foveal avascular zone area, and neovascularization in groups C and D. Overall, the cytokine profiles identified reflect a dynamic immunological evolution during DM1 and may serve as useful immune biomarkers to improve diagnosis, prognosis, and clinical management of the disease and its ocular complications. In the third study, mechanisms associated with disease progression were investigated by analyzing patients classified into two groups according to disease duration: Early (<1 year) and Advanced (>1 year), along with a healthy control group (H). Proteomic analysis of PBMCs and serum quantification of inflammatory mediators identified differentially expressed proteins involved in vesicular transport, immune responses, and metabolism. Several proteins associated with IL-12 signaling in macrophages (APOA2, APOC1, APOC3, PON1, AAK1, and CBL) were downregulated. Serum IL-12 levels were significantly higher in the Early-stage group compared with controls (p<0.001), while in the Advanced group only an upward trend was observed. CBL was proposed as a marker of immune status during DM1 progression, and HRG as a potential biomarker of secondary complications such as diabetic retinopathy. Taken together, these results provide key insights into the immunometabolic mechanisms underlying the disease and may guide novel diagnostic and therapeutic strategies. In summary, the findings of this work demonstrate that the progression of type 1 diabetes mellitus is marked by a dynamic interplay between inflammatory and regulatory mechanisms of the immune system. The specific cytokine and protein profiles identified not only reflect the immunological state across different disease stages but also emerge as potential biomarkers to improve diagnosis, prognosis, and the prevention of secondary complications such as diabetic retinopathy. Furthermore, the positive response observed to bioactive compounds with immunomodulatory properties suggests promising therapeutic potential aimed at modulating inflammation, optimizing clinical management, and promoting better longterm outcomes in patients with DM1.
RODIN. Repositorio de Objetos de Docencia e Investigación de la Universidad de Cádiz
Publication Artículo científico (JournalArticle)

Exploring proteomic immunoprofiles: common neurological and immunological pathways in multiple sclerosis and type 1 diabetes mellitus

  • Cano Cano, Fátima
  • Lara Barea, Almudena
  • Cruz Gómez, Álvaro Javier
  • Martín Loro, Francisco
  • Gómez Jaramillo, María Laura
  • González Montelongo, María del Carmen
  • Roca Rodríguez, María del Mar
  • Beltrán Camacho, Lucía
  • Forero, Lucía
  • González Rosa, Javier Jesús
  • Durán Ruiz, María del Carmen
  • Arroba Espinosa, Ana Isabel
  • Aguilar Diosdado, Manuel
Background: Interest in the study of type 1 diabetes mellitus (T1DM) and multiple sclerosis (MS) has increased because of their significant negative impact on the patient quality of life and the profound implications for the health care system. Although the clinical symptoms of T1DM differ from those of MS, such as pancreatic β-cell failure in T1DM and demyelination in the central nervous system (CNS) in MS, both pathologies are considered as autoimmune-related diseases with shared pathogenic pathways, which include autophagy, inflammation and degeneration, among others. Considering the challenges in obtaining pancreatic β-cells and CNS tissue from patients with T1DM and MS, respectively, it is fundamental to explore alternative methods for evaluating disease status. Proteomic analysis of peripheral blood mononuclear cells (PBMCs) is an ideal approach for identifying novel and potential biomarkers for both autoimmune diseases. Methods: We conducted a proteomic analysis of PBMCs from patients with T1DM and relapsing remitting Multiple Sclerosis (herein forth MS) patients (n = 9 per condition), using a label-free quantitative proteomics approach. The patients were diagnosed following the American Diabetes Association (ADA) criteria for T1DM and McDonald criteria for MS respectively, and were aged over 18 years and more than 2 years from the onset respectively. Results: A total of 2476 proteins were differentially expressed in PBMCs from patients with T1DM and MS patients compared with those form healthy controls (H). Predictive analysis highlighted 15 common proteins, up- or downregulated in PBMCs from patients with T1DM and MS patients vs. healthy controls, involved in the immune system activity (BTF3, TTR, CD59, CSTB), diseases of the neuronal system (TTR), signal transduction (STMN1, LAMTOR5), metabolism of nucleotides (RPS21), proteins (TTR, ENAM, CD59, RPS21, SRP9) and RNA (SRSF10, RPS21). In addition, this study revealed both shared and distinct molecular patterns between the two conditions. Conclusions: Compared with H, patients with T1DM and MS presented a specific expression pattern of common proteins has been identified. This pattern underscores the shared mechanisms involved in their immune responses and neurological complications, alongside dysregulation of the autophagy pathway. Notably, CSTB has emerged as a differential biomarker, distinguishing between these two autoimmune diseases.
RODIN. Repositorio de Objetos de Docencia e Investigación de la Universidad de Cádiz
Publication Artículo científico (JournalArticle)

Arylphthalide Delays Diabetic Retinopathy via Immunomodulating the Early Inflammatory Response in an Animal Model of Type 1 Diabetes Mellitus

  • Martín Loro, Francisco
  • Can Cano, Fátima
  • Ortega Agüera, María Jesús
  • Cuevas, Belén
  • Gómez Jaramillo, María Laura
  • González Montelongo, María del Carmen
  • Freisenhausen, Jan Cedric
  • Lara Barea, Almudena
  • Campos Caro, Antonio
  • Zubía Mendoza, Eva
  • Aguilar Diosdado, Manuel
  • Arroba Espinosa, Ana Isabel
Diabetic retinopathy (DR) is one of the most prevalent secondary complications associated with diabetes. Specifically, Type 1 Diabetes Mellitus (T1D) has an immune component that may determine the evolution of DR by compromising the immune response of the retina, which is mediated by microglia. In the early stages of DR, the permeabilization of the blood–retinal barrier allows immune cells from the peripheral system to interact with the retinal immune system. The use of new bioactive molecules, such as 3-(2,4-dihydroxyphenyl)phthalide (M9), with powerful anti-inflammatory activity, might represent an advance in the treatment of diseases like DR by targeting the immune systems responsible for its onset and progression. Our research aimed to investigate the molecular mechanisms involved in the interaction of specific cells of the innate immune system during the progression of DR and the reduction in inflammatory processes contributing to the pathology. In vitro studies were conducted exposing Bv.2 microglial and Raw264.7 macrophage cells to proinflammatory stimuli for 24 h, in the presence or absence of M9. Ex vivo and in vivo approaches were performed in BB rats, an animal model for T1D. Retinal explants from BB rats were cultured with M9. Retinas from BB rats treated for 15 days with M9 via intraperitoneal injection were analyzed to determine survival, cellular signaling, and inflammatory markers using qPCR, Western blot, or immunofluorescence approaches. Retinal structure images were acquired via Spectral-Domain–Optical Coherence Tomography (SD-OCT). Our results show that the treatment with M9 significantly reduces inflammatory processes in in vitro, ex vivo, and in vivo models of DR. M9 works by inhibiting the proinflammatory responses during DR progression mainly affecting immune cell responses. It also induces an anti-inflammatory response, primarily mediated by microglial cells, leading to the synthesis of Arginase-1 and Hemeoxygenase-1(HO-1). Ultimately, in vivo administration of M9 preserves the retinal integrity from the degeneration associated with DR progression. Our findings demonstrate a specific interaction between both retinal and systemic immune cells in the progression of DR, with a differential response to treatment, mainly driven by microglia in the anti-inflammatory action. In vivo treatment with M9 induces a switch in immune cell phenotypes and functions that contributes to delaying the DR progression, positioning microglial cells as a new and specific therapeutic target in DR.
RODIN. Repositorio de Objetos de Docencia e Investigación de la Universidad de Cádiz
Publication Artículo científico (JournalArticle)

Fluoro-labelled sp2-iminoglycolipids with immunomodulatory properties

  • Padilla Pérez, M. Carmen
  • Sánchez Fernández, Elena M.
  • González Bakker, Aday
  • Puerta, Adrián
  • Martín Loro, Francisco
  • García Fernández, José Manuel
  • Padrón, José M.
  • Arroba Espinosa, Ana Isabel
  • Ortiz Mellet, Carmen
The unique electronic properties of the fluorine atom make its strategic incorporation into a bioactive compound a very useful tool in the design of drugs with optimized pharmacological properties. In the field of the carbohydrates, its selective installation at C2 position has proven particularly interesting, some 2-deoxy-2-fluorosugar derivatives being currently in the market. We have now transferred this feature into immunoregulatory glycolipid mimetics that contain a sp2-iminosugar moiety, namely sp2-iminoglycolipids (sp2-IGLs). The synthesis of two epimeric series of 2-deoxy-2-fluoro-sp2-IGLs, structurally related to nojirimycin and mannonojirimycin, has been accomplished by sequential Selectfluor-mediated fluorination and thioglycosidation of sp2-iminoglycals. Exclusively the α-anomer is obtained regardless of the configurational profile of the sp2-IGL (D-gluco or D-manno), highlighting the overwhelming anomeric effect in these prototypes. Notably, the combination of a fluorine atom at C2 and an α-oriented sulfonyl dodecyl lipid moiety in compound 11 led to remarkable anti-proliferative properties, featuring similar GI50 values than the chemotherapy drug Cisplatin against several tumor cell lines and better selectivity. The biochemical data further evidence a strong reduction of the number of tumor cell colonies and apoptosis induction. Mechanistic investigations revealed that this fluoro-sp2-IGL induces the non-canonical activation mode of the mitogen-activated protein kinase signaling pathway, causing p38α autoactivation under an inflammatory context., 19 páginas
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Exploring the influence of the glycone space on the therapeutic potential of sp2-iminoglycolipids

  • Padilla, M. Carmen
  • Rodríguez Marín, Rocío
  • González Bakker, Aday
  • Khan, Adam N.
  • Bastardo, Mariana
  • Padrón, José M.
  • Martín Loro, Francisco
  • Arroba, Ana I.
  • García-Hernández, Raquel
  • Pérez-Victoria, José M.
  • García Fernández, José Manuel
  • Sánchez-Fernández, Elena M.
  • Ortiz Mellet, Carmen
Extensive structure-activity relationship studies performed on sp2-iminoglycolipids revealed the fundamental role played by a linear dodecylsulfide/sulfonyl aglycone chain on the anticancer, antiparasitic and immunomodulatory activities. However, the influence of structural modifications within the glycone region on the therapeutic performance remains largely underexplored. To address this gap, we have designed and stereoselectively synthesized a novel series of sp2-iminoglycolipids incorporating targeted modifications to the glycomimetic unit. These include C2 deoxygenation, bioisosteric replacement of the hydroxyl group with fluorine, and selective installation of aromatic hydrocarbons at the O3 position. Among the synthesized compounds, the fluorinated derivative (1R)-2-deoxy-1-S-dodecyl-2-fluoro-3-O-(p-fluorobenzyl)-5N,6O-oxomethylidene-1-sulfonylnojirimycin emerged as a promising multi-target candidate. Live-cell imaging in human cervical cancer (HeLa) cells revealed phenotypic markers characteristic of apoptotic cell death. Furthermore, clonogenic assays showed a significant, concentration-dependent reduction in the formation of cancer cell colonies, indicating impairment of tumor cell reproductive viability. Altogether, these data support a potent antiproliferative activity. This compound also exhibited strong antiparasitic activity, effectively inhibiting the growth of Leishmania donovani amastigotes at low micromolar concentrations. Additionally, it showed notable anti-inflammatory properties in microglial cells by downregulating the NLRP3 inflammasome signaling pathway following inflammatory stimulation, as evidenced by reduced caspase-1 activation and suppressed IL-1β release., This work was supported by grants funded by the Ministerio de Ciencia, Innovación y Universidades and the Agencia Estatal de Investigación MICIU/AEI/10.13039/501100011033 and “ERDF/EU” (grant numbers PID2022-141034OB-C21 to COM and EMSF; PID2022-138474OB-I00 to JMPV; PID2021-123059OB-I00 to JMP; PID2021-124247OB-C21 to JMGF). RRM is a FPI fellow (Grant number, PREP2022-000217). EMSF thanks the VII Plan Propio de Investigación y Transferencia from the University of Seville (VIIPPIT-2022-V.1, Modality A2). Technical assistance from the research support services of the University of Seville (CITIUS) is also acknowledged. AGB thanks the Asociación Española Contra el Cáncer (AECC) de Santa Cruz de Tenerife for predoctoral grant PRDTF233958GONZ. AIA was supported by grants from Instituto de Salud Carlos III (PI22/01718)., Peer reviewed